Separate the good effects from the bad in the brain itself
For years, semaglutide has offered people struggling with obesity a powerful tool — but one that often came wrapped in nausea and muscle loss, a trade-off that left many wondering whether the cure was worth the cost. Now, researchers at the University of Gothenburg have done something quietly profound: they have mapped, with cellular precision, which nerve cells in the brain stem are responsible for the drug's appetite-suppressing benefits, and found them to be distinct from those generating its side effects. Published in Cell Metabolism, the discovery does not yet change what patients experience, but it redraws the map of what might one day be possible — a treatment that speaks only to the parts of the brain worth listening to.
- Semaglutide's side effects — nausea, muscle loss — have quietly limited one of the most promising obesity treatments of the modern era, leaving patients caught between the disease and the remedy.
- Scientists at Sahlgrenska Academy traced the drug's activity neuron by neuron in mice, discovering that its beneficial effects cluster in a specific region of the brain stem called the dorsal vagal complex.
- When researchers stimulated those nerve cells directly — bypassing the drug entirely — mice ate less and lost weight; when those same cells were destroyed, the appetite benefits vanished while the nausea-linked effects stubbornly remained.
- This clean separation between benefit and side effect is the breakthrough: it proves the two responses are biologically distinct, not an inevitable package deal.
- The findings open a path toward next-generation GLP-1 therapies precisely engineered to activate only the cells that help, with potential reach into diabetes, addiction, and neurodegenerative disease research.
Semaglutide has reshaped obesity medicine, but it has always carried a difficult bargain — meaningful weight loss paired with nausea, muscle loss, and tolerability challenges that push some patients away. The central question driving a new study from the University of Gothenburg was whether that bargain was truly necessary, or whether the good and the bad could be pulled apart.
Working with mice at Sahlgrenska Academy, researchers tracked which brain cells activated when semaglutide was administered. They then stimulated those cells directly, without the drug — and the mice responded identically, eating less and losing weight. When those same cells were subsequently destroyed, the appetite benefits disappeared. But the side effects did not. Nausea and muscle loss persisted, pointing unmistakably to a different biological pathway.
The cells at the center of the benefit story live in the dorsal vagal complex, a deep brain stem region governing energy balance and appetite. PhD student Júlia Teixidor-Deulofeu, the study's first author, described these cells as necessary for weight loss but apparently uninvolved in producing nausea — a distinction that could guide an entirely new generation of targeted treatments.
Supervisor Linda Engström Ruud framed the broader stakes: as GLP-1 drugs are prescribed to ever-wider populations and tested against conditions from diabetes to neurodegeneration, understanding their precise mechanism becomes not just scientifically interesting but medically essential. This study, published in Cell Metabolism, is an early landmark — less a finished answer than a reliable map for the work ahead.
Semaglutide has become one of the most prescribed drugs for weight loss in recent years, but it comes with a familiar problem: nausea, muscle loss, and other side effects that make the treatment harder to tolerate than the condition itself. Now researchers at the University of Gothenburg have identified which parts of the brain are actually responsible for the drug's appetite-suppressing benefits—and crucially, which parts are causing the unwanted effects. The discovery, published in Cell Metabolism, suggests a path toward drugs that could deliver the weight loss without the nausea.
Semaglutide belongs to a class of medications called GLP-1 receptor agonists, drugs that have proven remarkably effective at reducing food intake and body weight. Beyond obesity treatment, they're already used for type 2 diabetes and are being investigated for substance use disorders and neurodegenerative diseases. But the side effects have limited their use for some patients. The question researchers wanted to answer was simple: Could you separate the good from the bad?
To find out, scientists at Sahlgrenska Academy worked with mice, tracking which nerve cells in the brain became active when semaglutide was administered. Once they identified these cells, they did something elegant: they stimulated them directly without giving the drug at all. The mice responded exactly as they had to semaglutide itself—they ate less and lost weight. When the researchers then destroyed these same nerve cells, the drug's appetite-suppressing effects largely disappeared. But here's the crucial part: the side effects like nausea and muscle loss remained. This told them something important about how the drug actually works.
The nerve cells they identified are located in a region called the dorsal vagal complex, deep in the brain stem. This area, it turns out, is where the brain regulates energy balance and appetite. By pinpointing these cells as the control center for semaglutide's beneficial effects, the researchers have essentially created a map for future drug development. Júlia Teixidor-Deulofeu, the study's first author and a PhD student at the university, explained the significance: these nerve cells are necessary for weight loss and appetite reduction but appear to have little to do with causing nausea. If future treatments could be designed to target only these cells, patients might get the weight loss without the side effects.
The implications extend beyond obesity. As Linda Engström Ruud, who supervised the research, noted, understanding exactly how these drugs work in the brain is essential as they're prescribed to more and more people and tested for new conditions. The better scientists understand the mechanism, the better they can refine it. This study represents an early but significant step—not just toward improved obesity treatments, but toward a deeper understanding of how the brain stem controls our most fundamental drives around food and energy.
Notable Quotes
These nerve cells are necessary for the effects that semaglutide has on weight and appetite, but do not appear to contribute significantly to side effects such as nausea.— Júlia Teixidor-Deulofeu, first author of the study
The better we understand how these drugs work, the greater the opportunity we have to improve them.— Linda Engström Ruud, researcher and supervisor
The Hearth Conversation Another angle on the story
So they found the specific cells that make semaglutide work for weight loss. But couldn't they have just looked at which cells activate when the drug is given?
They did look at that—but the clever part was what came next. They stimulated those cells without the drug and got the same result. That's how you know you've found the right target.
And when they destroyed the cells, the weight loss stopped but the nausea didn't. That's the key finding, isn't it?
Exactly. It means the nausea is coming from somewhere else entirely. The drug is hitting multiple targets in the brain, and they've now isolated which one does the useful work.
Does this mean we'll have a better drug soon?
Not soon, but it gives drug designers a blueprint. Instead of modifying semaglutide itself, they can now design something that only activates those specific cells in the dorsal vagal complex.
What about the muscle loss? Is that also separate from the appetite control?
The study suggests it is, yes. When they blocked the beneficial cells, muscle loss still happened. So that's another side effect they'd need to address separately.